Prevalence and Assessment of Metabolic Syndrome in Polycystic Ovarian Syndrome Among Women of Reproductive Age (Code-T0220)

Introduction: Polycystic Ovarian Syndrome (PCOS) is a common endocrine disorder affecting women of reproductive age, often leading to infertility, metabolic disturbances, and other long-term health complications. One of the significant comorbidities associated with PCOS is metabolic syndrome (MetS), which encompasses a cluster of conditions including hypertension, hyperglycemia, dyslipidemia, and central obesity.

Aim and Objective:

Aims:

  -To  study  the  clinical  profile  of  patients  with  PCOS .

 - To evaluate  and   study  the  prevalence  of  metabolic  syndrome  in  a  tertiary  care  hospital.

Objectives:

     1.To  define  a  patient  of  PCOS  as  per  Rotterdam’s  Criteria. 

1. Evaluation  of  women  with  PCOS  should  exclude  alternate  androgen  excess   disorders and  risk  factors  for  mood disorders, obstructive  sleep  apnea ,diabetes  and  cardiovascular  disorders.
2.   To  study  the  history, clinical  characteristics, anthropology ,lipid  profile and  USG  features  of  the  patient. 
3. To correlate  and  analysis  the  above  and  compare  with  other  studies.

Methods: A cross-sectional study was conducted involving 200 women diagnosed with PCOS, aged 18-40 years. Clinical and laboratory data were collected, including measurements of waist circumference, blood pressure, fasting blood glucose, and lipid profiles. The criteria for MetS were based on the modified National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines.

Results: The prevalence of MetS in women with PCOS was found to be 38%. Hypertension was the most common metabolic abnormality, followed by dyslipidemia and impaired fasting glucose. A significant correlation was observed between central obesity and insulin resistance, which are key components of both PCOS and MetS.

Conclusion: Metabolic syndrome is prevalent among women with PCOS, and its presence highlights the need for early screening and management of metabolic risk factors in this population. Lifestyle interventions and pharmacological treatment may reduce the long-term risks associated with MetS in women with PCOS.

Keywords: Polycystic Ovarian Syndrome, Metabolic Syndrome, Reproductive Age, Hypertension, Insulin Resistance, Dyslipidemia